<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec><h3>Background</h3>
<p>The early diagnosis and treatment of cholangiocarcinoma may benefit from specific tumor markers to be used in clinical practice.</p>
</sec>
<sec><h3>Objectives</h3>
<p>To investigate whether the pGCsiRNA-vascular endothelial growth factor (VEGF) can affect the onset and progression of cholangiocarcinoma and its possible mechanism using the targeted therapy of nude mouse model of cholangiocarcinoma with attenuated <italic>Salmonella</italic> carrying the plasmid pGCsiRNA-VEGF.</p>
</sec>
<sec><h3>Methods</h3>
<p>The nude mouse model of cholangiocarcinoma was established by tail vein injection of QBC939 cells and given attenuated <italic>Salmonella</italic> carrying the plasmid pGCsiRNA-VEGF. One month later, the tumor volume of nude mice was observed, and the tumor growth curve was plotted. The harvested tumors were weighed and detected for tissue structural changes and cell death status by hematoxylin–eosin staining. The protein and mRNA expressions of VEGF, matrix metalloproteinase 2 (MMP2), and MMP9 were detected by Western blotting and PCR, respectively.</p>
</sec>
<sec><h3>Results</h3>
<p>The tumor volume and weight of the pGCsiRNA-VEGF group were significantly smaller than those of the mock and the si-scramble groups (<italic>P</italic> &lt; 0.05). The expressions of VEGF, MMP2, and MMP9 at the transcriptional and translational levels were inhibited by pGCsiRNA-VEGF. PGCsiRNA-VEGF promoted tissue apoptosis and destroyed the tissue structure.</p>
</sec>
<sec><h3>Conclusions</h3>
<p>In vivo silencing of VEGF can affect cell survival and inhibit cell migration, invasion, and development, probably by enhancing apoptosis and inhibiting the expressions of MMP2 and MMP9.</p>
</sec>
</abstract>

Background
The early diagnosis and treatment of cholangiocarcinoma may benefit from specific tumor markers to be used in clinical practice.

Objectives
To investigate whether the pGCsiRNA-vascular endothelial growth factor (VEGF) can affect the onset and progression of cholangiocarcinoma and its possible mechanism using the targeted therapy of nude mouse model of cholangiocarcinoma with attenuated Salmonella carrying the plasmid pGCsiRNA-VEGF.

Methods
The nude mouse model of cholangiocarcinoma was established by tail vein injection of QBC939 cells and given attenuated Salmonella carrying the plasmid pGCsiRNA-VEGF. One month later, the tumor volume of nude mice was observed, and the tumor growth curve was plotted. The harvested tumors were weighed and detected for tissue structural changes and cell death status by hematoxylin–eosin staining. The protein and mRNA expressions of VEGF, matrix metalloproteinase 2 (MMP2), and MMP9 were detected by Western blotting and PCR, respectively.

Results
The tumor volume and weight of the pGCsiRNA-VEGF group were significantly smaller than those of the mock and the si-scramble groups (P < 0.05). The expressions of VEGF, MMP2, and MMP9 at the transcriptional and translational levels were inhibited by pGCsiRNA-VEGF. PGCsiRNA-VEGF promoted tissue apoptosis and destroyed the tissue structure.

Conclusions
In vivo silencing of VEGF can affect cell survival and inhibit cell migration, invasion, and development, probably by enhancing apoptosis and inhibiting the expressions of MMP2 and MMP9.

Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo

Jiangbei Branch of Zhongda Hospital of Southeast University

Asian Biomedicine

This work is licensed under the Creative Commons Attribution 4.0 International License.

Background
The early diagnosis and treatment of cholangiocarcinoma may benefit from specific tumor markers to be used in clinical practice.

Objectives
To...

Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo

Article Category: Original article

Publicado en línea: 30 abr 2024

Páginas: 61 - 68

DOI: https://doi.org/10.2478/abm-2024-0009

Palabras clave
cholangiocarcinoma, matrix metalloproteinase, mouse, treatment, vascular endothelial growth factor

© 2024 Shenglin Lu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo

Article Category: Original article

Publicado en línea: 30 abr 2024

Páginas: 61 - 68

DOI: https://doi.org/10.2478/abm-2024-0009

Palabras clavecholangiocarcinoma, matrix metalloproteinase, mouse, treatment, vascular endothelial growth factor

© 2024 Shenglin Lu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Palabras clave
cholangiocarcinoma, matrix metalloproteinase, mouse, treatment, vascular endothelial growth factor